Cambridge Investment Research Advisors Inc. trimmed its holdings in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 46.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,898 shares of the company’s stock after selling 5,984 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Crispr Therapeutics were worth $420,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also made changes to their positions in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Crispr Therapeutics by 13.6% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock worth $118,000 after buying an additional 343 shares during the last quarter. Traynor Capital Management Inc. grew its stake in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after buying an additional 375 shares during the last quarter. Commonwealth Equity Services LLC grew its stake in Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after buying an additional 386 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in Crispr Therapeutics during the 4th quarter worth $26,000. Finally, Webster Bank N. A. purchased a new position in Crispr Therapeutics during the 4th quarter worth $26,000. Hedge funds and other institutional investors own 51.39% of the company’s stock.

Several brokerages recently weighed in on CRSP. William Blair restated a “buy” rating on shares of Crispr Therapeutics in a research note on Thursday, February 13th. Piper Sandler restated a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Thursday, February 13th. TheStreet upgraded Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. BidaskClub upgraded Crispr Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday. Finally, Piper Jaffray Companies restated a “buy” rating and set a $104.00 target price on shares of Crispr Therapeutics in a research note on Monday, December 16th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the company’s stock. Crispr Therapeutics has an average rating of “Buy” and an average target price of $78.29.

Shares of CRSP stock opened at $53.03 on Monday. The stock has a market cap of $3.23 billion, a PE ratio of 54.67 and a beta of 3.26. The business has a 50-day simple moving average of $56.62 and a 200-day simple moving average of $53.20. Crispr Therapeutics AG has a 52-week low of $30.83 and a 52-week high of $74.00.

Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $1.19. The business had revenue of $77.00 million during the quarter, compared to analysts’ expectations of $39.08 million. Crispr Therapeutics had a return on equity of 11.74% and a net margin of 23.09%. The company’s revenue for the quarter was up 76900.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.92) EPS. As a group, research analysts expect that Crispr Therapeutics AG will post -4.46 EPS for the current year.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: What are the benefits of investing in REITs?

Institutional Ownership by Quarter for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link